TEST:

PanHeme assay

Our NGS testing found tier 1 or 2 variants in the majority of cases, supporting its use in the clinical setting. Additionally, a subset of variants identified with the pan-Heme list likely represents mutations of clonal hematopoiesis of indeterminate potential, which could be removed with a more lymphoma-specific gene list. Given these findings, and a growing number of targets in indolent B cell lymphomas, future studies focusing on evaluation of a lymphoma-specific gene list is of interest for clinical validation and implementation.

The MPN NGS panel demonstrated excellent clinical utility, as 96% (26/27) of significant JAK2/CALR/MPL variants were identified in our cohort. The detection rate of predominately JAK2 variants with rare CALR and MPL variants is in line with the current literature. Based on the findings of patients that underwent the pan-heme panel, potential expansion of coverage regions in JAK2 to include additional exons (such as exon 16) could further improve the detection rate.

"US-based Roswell Park Comprehensive Cancer Center has introduced the new advanced, high-speed blood cancer test, PanHeme...Leveraging next-generation gene sequencing technology, the new test will enable the diagnosis of blood cancers such as multiple myeloma, lymphoma and leukaemia."

"Roswell Park Cancer Center said this week that Agilent Technologies has licensed its blood cancer assay, PanHeme...Under the licensing agreement, Agilent is now able to commercialize the assay worldwide, supported by its SureSelect XT HS2 library preparation and target enrichment chemistry, Magnis NGS Prep system, Bravo automation platform, and Alissa secondary analysis software."